Although PD-1/PD-L1 anti-body as neoadjuvant therapy has been used in early stage NSCLC in clinical trials recently (21–24), there are no transcriptomic data of the tumor before treatment at present, so the regimen we proposed could not be validated in this study. The gene discussed is CD274; the disease is neoplasm.